Revolution Medicines: Upcoming Investor Conferences Overview

Author: Thomas Cooper Updated: 02-24-2025 04:17 PM

Upcoming Investor Conferences for Revolution Medicines

Revolution Medicines, Inc. (NASDAQ: RVMD) has announced exciting news for investors and stakeholders alike. The company is actively involved in three key investor conferences that will showcase their advancements in the field of oncology and provide insights into their innovative targeted therapies.

Details of the Participation

The participation details for the conferences are as follows:

TD Cowen Annual Healthcare Conference

Revolution Medicines' CEO, Mark A. Goldsmith, M.D., Ph.D., will lead a fireside chat on Monday, March 3 at 1:50 p.m. ET. This conference presents a great opportunity to explore the company’s pipeline and strategic plans.

Barclays Global Healthcare Conference

Following this, on Tuesday, March 11 at 8:00 a.m. ET, Dr. Goldsmith will present at the Barclays 27th Annual Global Healthcare Conference. Attendees can expect discussions surrounding the firm’s commitments and novel approaches to cancer treatment.

2025 Leerink Partners Global Healthcare Conference

The third conference where Revolution Medicines will be featured is the 2025 Leerink Partners Global Healthcare Conference. This session will take place on Wednesday, March 12 at 2:20 p.m. ET, where the company will discuss its milestones and strategic vision.

How to Access the Webcasts

For those interested in following these discussions live, the company will provide access to webcasts from each conference. After the events, replays will be made available for at least 14 days. This is a valuable chance for investors to stay informed about the latest developments in oncology and Revolution Medicines' contributions to the field.

About Revolution Medicines, Inc.

As a late-stage clinical oncology firm, Revolution Medicines focuses on creating novel targeted therapies for patients facing RAS-addicted cancers. The company champions a rigorous R&D pipeline featuring RAS(ON) inhibitors like daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805). These drugs are at various stages of clinical development, striving to provide critical treatment options for patients dealing with difficult oncogenic variants.

In addition to these notable compounds, Revolution Medicines is exploring other selective mutant inhibitors that promise to expand their effectiveness against resistant cancer types, showcasing their commitment to combating serious health challenges.

Contact Information

For further inquiries or media-related questions, Revolution Medicines can be reached through:

Email: media@revmed.com
Email: investors@revmed.com

Frequently Asked Questions

1. What is Revolution Medicines known for?

Revolution Medicines is recognized for developing targeted therapies for RAS-addicted cancers.

2. Who will be presenting at the investor conferences?

Mark A. Goldsmith, M.D., Ph.D., the CEO, will be presenting at all three upcoming conferences.

3. How can I access the investor calls?

Live webcasts will be available through the company’s website and can be accessed for 14 days post-event as recorded sessions.

4. What are RAS(ON) inhibitors?

RAS(ON) inhibitors are a class of drugs being developed by Revolution Medicines to target and suppress specific oncogenic variants of the RAS proteins in cancer cells.

5. How can I learn more about Revolution Medicines and their pipeline?

For more information, visit their official website or reach out via provided email contacts.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.